Cooley advised Candid Therapeutics, a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), on its agreement to be acquired by UCB, a global biopharmaceutical company, for up to $2.2 billion.